Search for: "PFIZER"
Results 1781 - 1800
of 4,632
Sort by Relevance
|
Sort by Date
2 Mar 2014, 11:03 pm
The Judicial Panel on Multidistrict Litigation has recently approved a motion to consolidate federal lawsuits filed against Pfizer Inc. due to Lipitor side effects. [read post]
1 Mar 2014, 8:55 pm
Pfizer (Fed. [read post]
28 Feb 2014, 11:23 am
Pfizer, Inc., No. 12-60861, 2014 WL 661058 (5th Cir. [read post]
27 Feb 2014, 8:39 am
Clark, Pfizer’s chief security officer, who added that Chinese authorities were cooperative. [read post]
27 Feb 2014, 6:00 am
We watched some of the recently concluded Winter Olympics. [read post]
24 Feb 2014, 7:23 am
JPML Decides to Consolidate Lipitor Personal Injury Cases in South Carolina Federal Court On Tuesday, February 18th, the Judicial Panel on Multidistrict Litigation (JPML) reconsidered Lipitor plaintiffs’ request to form a multidistrict litigation against Pfizer, and concluded that there were enough lawsuits to proceed. [read post]
21 Feb 2014, 8:53 am
Not too long ago we were asked what we thought about warning claims involving medication guides. [read post]
21 Feb 2014, 8:30 am
SEC claims drunk lawyer had insider tipple By Kara Scannell in FT.com The SEC sued Tibor Klein, a New York investment adviser, in September for allegedly buying securities of King Pharmaceuticals after learning from one of his clients that the drug company was in talks to be acquired by Pfizer. [read post]
20 Feb 2014, 9:39 am
See Pfizer, Inc. v. [read post]
20 Feb 2014, 8:36 am
The policy's staunch critics include the Pharmaceutical Research and Manufacturer's of America, the Maine Pharmacy Association and big-name drug manufacturers such as Pfizer and Johnson & Johnson. [read post]
19 Feb 2014, 6:57 am
• Novartis Pharmaceuticals Corporation • Pfizer, Inc. [read post]
18 Feb 2014, 12:43 pm
See Pfizer, Inc. v. [read post]
12 Feb 2014, 7:36 am
Abstract: The January 2012 decision of the Italian Competition Authority (“ICA”) to fine Pfizer and Pharmacia €10.6 million is an illustration of the more aggressive trend taken by competition authorities in the pharmaceutical sector. [read post]
10 Feb 2014, 10:00 pm
According to the court’s rules, the non-precedential designation of Pfizer Inc. v. [read post]
10 Feb 2014, 9:50 pm
Pfizer Inc. et al. v. [read post]
10 Feb 2014, 2:01 am
Perhaps the most important exclusion from patentability, discussed further below, is India’s Section 3(d).The authors cited Pfizer v. [read post]
7 Feb 2014, 6:04 am
Relating to the drug Lyrica, the CAFc decision has some interesting statements about enablement and written description in the context of covering enantiomers from racemates. [read post]
6 Feb 2014, 9:59 pm
By Andrew Williams -- The standard of review at the Federal Circuit is important. [read post]
3 Feb 2014, 4:54 am
Italy: Consiglio di Stato reinstates original Pfizer Xalatan order" is the title of a fascinating guest post on The SPC Blog by Gian Paulo Di Santo (Pavia & Ansaldo, Milan) on the Consiglio Di Stato ruling on the legality of Pfizer's patent/SPC strategy for its Xalatan latanoprost product. [read post]
31 Jan 2014, 2:00 pm
Pfizer, Inc., 720 F.3d 739, 747 (8th Cir. 2013) (same). [read post]
